Schrödinger: An Interesting Investment With Immense Potential
Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Business Wire13h
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...
GlobalData on MSN20h
Alphamab doses first subject in trial of JSKN003 for ovarian cancer
Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Al ...
Daily21h
FDA approves drug combination for complicated intra-abdominal infections
AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...
Sierra Sun Times22h
NIH-Funded Clinical Trial will Evaluate New Dengue Therapeutic
If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...
Gesynta Pharma Receives $27 Million For Endometriosis Novel Therapy Drug
Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.
OS Therapies gears up for FDA meeting on cancer drug
NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a small-cap biotech firm with a market capitalization of $42 million focusing on cancer treatment solutions, has announced the completion of its Phase 2b ...